Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) EBT Margin: 2020-2025

Historic EBT Margin for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -4,249.23%.

  • Insight Molecular Diagnostics' EBT Margin rose 750294.00% to -4,249.23% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,392.91%, marking a year-over-year increase of 473614.00%. This contributed to the annual value of -3,245.14% for FY2024, which is 157275.00% down from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' EBT Margin stood at -4,249.23%, which was down 123.64% from -1,900.00% recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' EBT Margin ranged from a high of 2,006.40% in Q1 2023 and a low of -11,752.17% during Q3 2024.
  • Its 3-year average for EBT Margin is -3,325.60%, with a median of -2,262.92% in 2024.
  • In the last 5 years, Insight Molecular Diagnostics' EBT Margin surged by 5,414,713bps in 2021 and then tumbled by 1,023,959bps in 2024.
  • Quarterly analysis of 5 years shows Insight Molecular Diagnostics' EBT Margin stood at -997.16% in 2021, then crashed by 338,861bps to -4,385.77% in 2022, then crashed by 76,678bps to -5,152.55% in 2023, then surged by 288,963bps to -2,262.92% in 2024, then soared by 750,294bps to -4,249.23% in 2025.
  • Its EBT Margin stands at -4,249.23% for Q3 2025, versus -1,900.00% for Q2 2025 and -318.01% for Q1 2025.